

Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria (Vpriv® Criteria)
Original Development Date:	
Revision Date:	
	May 21, 2012, January 18, 2019

VPRIV® (velaglucerase alfa)

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- Patient must be ≥ 4 years of age.
- Must have a documented (in "health condition" or medical records) diagnosis of Gaucher Disease Type I.

DOSING and ADMINISTRATION:

➤ 60 Units/kg administered every other week as a 60-minute intravenous infusion.

